Saikrishna Kandalam
Global Heor Lead @Novo Nordisk
Signup · Get unlimited contacts
WORK HISTORY
Global Heor Lead @Novo Nordisk
Bengaluru, IN
Lead global HEOR evidence strategy for an in market and pipeline portfolio, aligning evidence generation with launch timelines, competitive landscape, and HTA requirements in priority markets.• Steer end to end delivery of SLRs/TLRs, ITC/NMAs, cost effectiveness analyses, and budget impact models through external vendors and internal partners, ensuring methodological rigor and HTA fitness for purpose.• Develop and maintain global HEOR/market access plans, integrating clinical, economic, and humanistic evidence to support pricing, reimbursement, and payer value communication.• Enable regional and local market access teams via global evidence packages, localization guidance, and input into HTA/payer engagement strategies.• Collaborate cross functionally with Medical Affairs, Commercial, Clinical, and Regulatory teams to ensure evidence strategies are aligned with asset strategy and lifecycle plans.• Provide HEOR input into study designs, protocols, and real-world evidence plans to ensure endpoints and comparators meet payer and HTA expectations. • Oversee budget, timelines, and vendor governance for HEOR programs, including contract negotiation, performance tracking, and quality oversight.
EDUCATION
Andhra University
Master’s Degree, Pharmaceutical Sciences major in Pharmacology
Liverpool John Moores University
Master of Business Administration - MBA, Business Administration and Management, General
Université d'Angers
Doctor of Philosophy (Ph.D.), Experimental and clinical pharmacology (Neuroscience)
Institute of Management Technology, Ghaziabad
Post Graduate Diploma in Management, Business Administration, Management and Operations
Université catholique de Louvain
Doctor of Philosophy (Ph.D.), Biomedical and Pharmaceutical Sciences
Jawaharlal Nehru Technological University
Bachelor’s Degree, Pharmacy
SKILLS
ABOUT SAIKRISHNA KANDALAM
I am a HEOR and market access leader with 12+ years of experience translating clinical and economic evidence into payer‑relevant value stories for global pharma and medical devices. I currently lead global HEOR strategy for Novo Nordisk’s diabetes portfolio, shaping evidence investments and HTA plans across both in‑market and pipeline assets.My work spans systematic and targeted literature reviews, ITC/NMAs, CEA/BIM models, and HTA evidence packages that support pricing and reimbursement decisions in priority markets. I have led numerous evidence synthesis projects and cost‑effectiveness/budget impact models, partnering closely with Market Access, Medical Affairs, and affiliate teams across regions.My background includes a PhD in Experimental & Clinical Pharmacology (Neuroscience), an MBA in Leadership & Strategy, and a strong publication record in HEOR and translational research. I enjoy building high‑performing teams, strengthening vendor partnerships, and coaching talent on HEOR methods, HTA expectations, and communication with payers and internal stakeholders.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.